Cohen Lawrence B raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,185 shares of the medical research company’s stock after purchasing an additional 195 shares during the period. Thermo Fisher Scientific accounts for 2.1% of Cohen Lawrence B’s holdings, making the stock its 18th biggest holding. Cohen Lawrence B’s holdings in Thermo Fisher Scientific were worth $2,991,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its stake in Thermo Fisher Scientific by 0.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,706,326 shares of the medical research company’s stock valued at $605,651,000 after purchasing an additional 17,860 shares during the last quarter. Capital Investment Advisors LLC bought a new position in Thermo Fisher Scientific during the first quarter worth $203,000. Truvestments Capital LLC bought a new stake in Thermo Fisher Scientific in the first quarter valued at $29,000. Farmers & Merchants Trust Co of Chambersburg PA increased its position in shares of Thermo Fisher Scientific by 168.0% during the first quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 201 shares of the medical research company’s stock worth $55,000 after acquiring an additional 126 shares in the last quarter. Finally, Portland Global Advisors LLC purchased a new position in Thermo Fisher Scientific during the first quarter worth about $217,000. 88.21% of the stock is owned by hedge funds and other institutional investors.
TMO opened at $275.17 on Wednesday. The company has a current ratio of 1.49, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $110.68 billion, a PE ratio of 24.75, a price-to-earnings-growth ratio of 1.81 and a beta of 1.11. Thermo Fisher Scientific Inc. has a twelve month low of $208.34 and a twelve month high of $305.45. The company has a 50-day moving average of $288.15.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s payout ratio is 6.83%.
Several research analysts recently weighed in on the stock. Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, May 30th. They set an “outperform” rating on the stock. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price target on the stock in a report on Wednesday, June 12th. Bank of America restated a “buy” rating and set a $300.00 price target (up from $285.00) on shares of Thermo Fisher Scientific in a report on Tuesday, April 16th. UBS Group boosted their price target on shares of Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday, May 23rd. Finally, Credit Suisse Group restated a “buy” rating and set a $310.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, July 31st. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $303.17.
In other Thermo Fisher Scientific news, Director C Martin Harris sold 275 shares of the business’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total value of $74,450.75. Following the transaction, the director now directly owns 6,433 shares in the company, valued at $1,741,606.09. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction dated Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total transaction of $14,241,500.00. Following the completion of the transaction, the chief executive officer now owns 342,193 shares in the company, valued at $97,466,832.19. The disclosure for this sale can be found here. Over the last quarter, insiders sold 52,775 shares of company stock worth $14,986,676. Corporate insiders own 0.45% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Recommended Story: What is a Buy-Side Analyst?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.